CTOs on the Move

SPARC

www.sparc.co

 
Cannabis dispensaries in San Francisco, Santa Rosa, and Sebastopol, SPARC offers same-day cannabis delivery in San Francisco and Sonoma County.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.sparc.co
  • 1256, Mission Street
    San Francisco, CA USA 94103
  • Phone: 415.987.5365

Executives

Name Title Contact Details

Similar Companies

Imaging Systems Inc

Imaging Systems Inc is a Peachtree City, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apricus Biosciences Inc.

Apricus Biosciences Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in San Diego, CA. To find more information about Apricus Biosciences Inc., please visit www.apricusbio.com

Puritan's Pride

Puritan's Pride is a Bohemia, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KPR

KPR is a Granada Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.